Intratumoral MMR Vaccine Injection in Borderline Resectable/Unresectable Pancreatic Cancer

By doing this study, it is the hope to learn whether an injection of the measles, mumps, rubella (MMR) vaccine developed by Merck \& Co. (Merck's M-M-R® II) into the tumor is safe and effective in making the tumor smaller.

Trial Details

NCT ID
NCT07539155
Phase
PHASE1 / PHASE2
Sponsor
University of Arkansas
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Intratumoral MMR Injection
Locations (sample)
  • Little Rock, Arkansas, United States|34.74648,-92.28959

Key Eligibility Criteria

  • Age ≥ 18 years.
  • Pathologically proven locally advanced adenocarcinoma of pancreas.
  • Borderline resectable pancreatic cancer that is determined to be unresectable following completion of SoC chemotherapy and RT as evidenced by any o…
  • Encasement of gastroduodenal artery up to the common hepatic artery/short segment encasement or abutment of the hepatic artery, but without extensi…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →